Regeneron Pharmaceuticals, Inc. (REGN) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in Tarrytown, NY, United States. The current CEO is Leonard S. Schleifer.
REGN has IPO date of 1991-04-02, 15,158 full-time employees, listed on the NASDAQ Global Select, a market capitalization of $78.5B.
Regeneron Pharmaceuticals, Inc. is a global biopharmaceutical company that discovers, develops, manufactures, and commercializes innovative medicines for serious diseases. The company's marketed portfolio includes EYLEA for retinal diseases, Dupixent for atopic dermatitis and asthma, Libtayo for cutaneous squamous cell carcinoma, Praluent for cardiovascular disease, Kevzara for rheumatoid arthritis, and several other specialized therapies for infectious, rare, and cancerous conditions. Regeneron maintains extensive collaboration agreements with leading pharmaceutical and biotechnology companies including Sanofi, Bayer, Roche, and AstraZeneca, as well as strategic partnerships with research institutions and government health agencies. Founded in 1988 and headquartered in Tarrytown, New York, the company focuses on high-value therapeutic areas including ophthalmology, immunology, cardiovascular disease, and oncology.
